<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01455571</url>
  </required_header>
  <id_info>
    <org_study_id>HM-PHI-101</org_study_id>
    <nct_id>NCT01455571</nct_id>
  </id_info>
  <brief_title>Phase I Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of HM781-36B in Patients With Advanced Solid Tumors</brief_title>
  <official_title>Phase I Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of HM781-36B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to determine the maximum tolerated dose (MTD) of&#xD;
      HM781-36B.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Besides the main objective, there are 3 other objectives as follows:&#xD;
&#xD;
        1. To determine dose-limiting toxicity (DLT) of HM781-36B&#xD;
&#xD;
        2. To characterize the pharmacokinetics of HM781-36B, following oral administration of&#xD;
           HM781-36B&#xD;
&#xD;
        3. To evaluate anticancer activity of HM781-36B in patients with advanced solid&#xD;
           malignancies Groups of 3 patients per cohort or dose level will be treated with&#xD;
           escalating doses of HM781-36B&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD determination</measure>
    <time_frame>Dose limiting Toxicity will be evaluated on Day 21 during Cycle 1</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>HM781-36B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose : 0.5mg, 1mg, 2mg, 4mg, 8mg, 12mg, 16mg, 20mg,...</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM781-36B</intervention_name>
    <description>Q1DX14/2W for 3W HM781-36B</description>
    <arm_group_label>HM781-36B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1) Histologically or cytologically confirmed advanced solid tumor 2) Patients who have&#xD;
             experienced progressive disease despite of conventional anticancer therapy. Patients&#xD;
             who cannot expect effective treatment or prolonged survival with conventional&#xD;
             anticancer therapy 3) Previous chemotherapy, radiotherapy and surgical operation are&#xD;
             allowed if they are discontinued for at least 4 weeks prior to D0 and all adverse&#xD;
             events are resolved 4) Aged ≥19 5) Eastern Cooperative Oncology Group (ECOG)&#xD;
             performance score of less than or equal to 2 6) A life expectancy greater than 12&#xD;
             weeks 7) Adequate bone marrow (WBC≥4,000/mm3 platelet≥100000/mm3, hemoglobin≥9.0g/dl&#xD;
             and ANC≥ 1500/mm3, renal (Creatinine≤1.5mg/dl) and liver function (AST/ALT/ALP ≤ 3 x&#xD;
             upper limit of normal and total bilirubin≤2mg/dl) and no abnormal heart and lung&#xD;
             function However, AST/ALT/ALP ≤ 5 x upper limit of normal for patients with liver&#xD;
             metastases and ALP level ≤ 5 x upper limit of normal for patients with bone metastases&#xD;
             are allowed 8)Subjects must provide written informed consent prior to performance of&#xD;
             study specific procedures or assessments, and must be willing to comply with treatment&#xD;
             and follow up assessments and procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1) Patients with hematopoietic malignancies,uncontrolled infection, ileus, CNS&#xD;
             metastasis.&#xD;
&#xD;
             2) Patients who have undergone hematopoietic stem cell transplantation (HSCT) or are&#xD;
             candidates for planned HSCT 3) Class III or IV heart failure (NYHA Class) or LVEF&lt;40%&#xD;
             4) Patients who have GI malabsorption or difficulty taking oral medication 5) Patients&#xD;
             who have psychiatric or congenital disorder 6) Subjects who, in the investigator's&#xD;
             opinion, cannot be treated per protocol due to functional impairments 7) Pregnant or&#xD;
             breast-feeding patients; Women of childbearing potential without adequate&#xD;
             contraception (Men must use adequate contraception.) 8) Subjects who have no intention&#xD;
             of following the requirements of the protocol or the follow-up management. Subjects&#xD;
             who cannot be followed up regularly due to psychological, social, family, logistic,&#xD;
             and geographical reasons 9) Subjects who were administered with other investigational&#xD;
             products within 30 days before screening.&#xD;
&#xD;
             10) Subjects who, in the investigator's opinion, cannot be participated.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>October 18, 2011</study_first_submitted>
  <study_first_submitted_qc>October 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2011</study_first_posted>
  <last_update_submitted>February 24, 2014</last_update_submitted>
  <last_update_submitted_qc>February 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <pending_results>
    <submitted>May 15, 2015</submitted>
    <returned>June 5, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

